An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of INCSHR01210 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs INCSHR 1210 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 14 Sep 2017 Planned number of patients changed from 27 to 24.
- 14 Sep 2017 Status changed from active, no longer recruiting to recruiting.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress